Weiss, Tracey
Near, Aimee M.
Zhao, Xiaohui
Ramey, Dena Rosen
Banerji, Tania
Xie, Handing
Nathan, Steven D.
Funding for this research was provided by:
Merck
Article History
Received: 18 April 2023
Accepted: 6 October 2023
First Online: 21 November 2023
Declarations
:
: All data were accessed in compliance with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996 regulations (HIPAA). All databases used are de-identified and fall under the US Department of Health and Human Services Policy for the Protection of Human Subjects, and therefore informed consent and Institutional Review Board approval were not required.
: Not applicable.
: Weiss and Ramey are employees of Merck & Co., Inc. Near and Zhao are employees of IQVIA, Inc., which received consulting fees for conducting this study. Xie and Banerji were employees of IQVIA at the time of study conduct. Nathan has received consulting fees and serves on the advisory board for Merck &Co., Inc., United Therapeutics Corporation, Bellerophon Therapeutics, Third Pole Therapeutics and F. Hoffmann-La Roche AG.